Skip to content

Correlation of Peripheral Blood Macrophage DPEP2 with Inflammation and Prognosis in Sepsis: A Single-center, Prospective Observational Study

Correlation of Peripheral Blood Macrophage DPEP2 with Inflammation and Prognosis in Sepsis: A Single-center, Prospective Observational Study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400091373
Enrollment
Unknown
Registered
2024-10-28
Start date
2024-11-01
Completion date
Unknown
Last updated
2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

Non-infected controls:None

Sponsors

Zhongshan Hospital Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Septic patients (1) 18-85 years old, male or female; (2) Clearly with bacterial infection (types of pathogens and primary disease are not limited); (3) SOFA= 2; (4)From whom written informed consent is obtainable either from the patient or from a legal representative. 2. Non-infected controls (1) 18-85 years old, male or female; (2) No evidence of infection; (3) From whom written informed consent is obtainable either from the patient or from a legal representative.

Exclusion criteria

Exclusion criteria: (1) >85 years old or <18 years old; (2) Participation in Organ transplant within a month; (3) Patients with active cancer, patients with a history of cancer were not excluded; Active cancer patients include patients who are planned for undergoing cancer surgery, are receiving anticancer drug(s) and/or radiotherapy, and have recurrent, metastatic, and/or inoperable cancer. Patients with cancer history include the tumor has been successfully treated and patients is not currently in the treatment phase, or the tumor has been resected and there is no evidence of recurrence, or patients are currently receiving adjuvant therapy (e.g., Lupron or tamoxifen) for prophylaxis. (4) Patients with human immunodeficiency virus/acquired immunodeficiency syndrome; (5) Patients with autoimmune diseases; (6) Participation in other drug trials in the 30 days prior to enrollment; (7) Parturient or breast-feeding women.

Design outcomes

Primary

MeasureTime frame
The propotion of DPEP2+ macrophage in peripheral blood;Inflammatory markers in peripheral blood;

Secondary

MeasureTime frame
SOFA score;In-hospital mortality;28-day post-discharge mortality;Concentration of DPEP2 in peripheral blood;

Countries

China

Contacts

Public ContactJing Zhong

Zhongshan Hospital Fudan University

jzhong12@fudan.edu.cn+86 138 1818 5296

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026